Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome
- Iurlo, Alessandra
- Nobili, Alessandro
- Latagliata, Roberto
- Bucelli, Cristina
- Castagnetti, Fausto
- Breccia, Massimo
- Abruzzese, Elisabetta
- Cattaneo, Daniele
- Fava, Carmen
- Ferrero, Dario
- Gozzini, Antonella
- Bonifacio, Massimiliano
- Tiribelli, Mario
- Pregno, Patrizia
- Stagno, Fabio
- Vigneri, Paolo
- Annunziata, Mario
- Cavazzini, Francesco
- Binotto, Gianni
- Mansueto, Giovanna
- Russo, Sabina
- Falzetti, Franca
- Montefusco, Enrico
- Gugliotta, Gabriele
- Storti, Sergio
- D'Addosio, Ada M
- Scaffidi, Luigi
- Cortesi, Laura
- Cedrone, Michele
- Rossi, Antonella Russo
- Avanzini, Paolo
- Mauro, Endri
- Spadea, Antonio
- Celesti, Francesca
- Giglio, Gianfranco
- Isidori, Alessandro
- Crugnola, Monica
- Calistri, Elisabetta
- Sorà, Federica
- Rege Cambrin, Giovanna
- Sica, Simona
- Luciano, Luigiana
- GALIMBERTI, SARA
- Orlandi, Ester M
- Bocchia, Monica
- Tettamanti, Mauro
- Alimena, Giuliana
- Saglio, Giuseppe
- Rosti, Gianantonio
- Mannucci, Pier Mannuccio
- Cortelezzi, Agostino
Publication date
January 2016
DOI ISSN
1949-2553 Language
English Citation count (estimate)
4Abstract
About 40% of all patients with chronic myeloid leukemia are currently old or very old. They are effectively treated with imatinib, even though underrepresented in clinical studies. Furthermore, as it happens in the general population, they often receive multiple drugs for associated chronic illnesses. Aim of this study was to assess whether or not in imatinib-treated patients aged >75 years the exposure to polypharmacy (5 drugs or more) had an impact on cytogenetic and molecular response rates, event-free and overall survival, as well as on hematological or extra-hematological toxicity
Add to ORKG